Pharmaceuticals, Biotechnology and Life Sciences
PRESS RELEASE Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Updated overall survival…
Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease…
IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal…
– Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients…
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improveORR of 85% (23 of 27…
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed…
Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide update on…
Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined…
Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor…
Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract highlights 3/10 (30%) partial responses…